Latest Breaking News On - Breakthrough designations - Page 1 : comparemela.com

Soleno Therapeutics Announces Oral Presentation featuring DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome at ENDO 2024

Soleno Therapeutics, Inc. announced that data from the randomized withdrawal period of Study C602 of DCCR extended-release tablets in Prader-Willi Syndrome will be featured in an oral presentation.

United statesSoleno therapeutics incPrader willi syndrome association united statesMeeting of the endocrine societyFoundation for prader willi researchSoleno therapeuticsPrader willi syndromeAnnual meetingEndocrine societyPrader willi researchOrphan drug designationFast trackBreakthrough designations

Soleno Therapeutics Announces Oral Presentation featuring DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome at ENDO 2024

Soleno Therapeutics Announces Oral Presentation featuring DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome at ENDO 2024
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United statesBrian ritchieQueen mary university londonPrader willi syndrome association united statesPhd barts healthSoleno therapeutics incLifesci advisorsMeeting of the endocrine societyFoundation for prader willi researchTherapeutics announces oral presentationDiazoxide cholineExtended release tabletsPrader willi syndromeAnnual meetingEndocrine societyExtended release tablets worsens hyperphagia

Soleno Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results

Soleno Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United statesLauren budesheimMeredith manningBrian ritchieDairine dempseyManish bhatnagarPrader willi syndrome association united statesSoleno therapeutics incCompany phaseSecurities exchangeLifesci advisorsDrug administrationFoundation for prader willi researchTherapeutics provides corporate updateReports first quarterRecent corporate

Soleno Therapeutics Announces Peer-Reviewed Publication of Data Comparing DCCR Treatment to the Natural History of Prader-Willi Syndrome

REDWOOD CITY, Calif., April 30, 2024 Soleno Therapeutics, Inc. , a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced the.

United statesJennifer millerBrian ritchieShawn mccandlessPrader willi syndrome association united statesGlobenewswire incResearch programsSecurities exchangeSoleno therapeutics incLifesci advisorsCompany phaseFoundation for prader willi researchDiazoxide cholineHistory studyHyperphagia questionnaireClinical trials

Soleno Therapeutics Receives Breakthrough Therapy Designation from U S FDA for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome (PWS)

Soleno Therapeutics Receives Breakthrough Therapy Designation from U S FDA for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome (PWS)
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United statesBrian ritchieManish bhatnagarSoleno therapeutics incFoundation for prader willi researchDrug administrationLifesci advisorsPrader willi syndrome association united statesSecurities exchangeDiazoxide cholineExtended release tabletsPrader willi syndromeEver breakthrough designationDrug being developedNew drug applicationBreakthrough therapy designation